Abstracts n = 105) with an asthma diagnosis, reported their side effects on the ICQ. We hypothesised that construct validity was supported on a scale and domain level, if scores demonstrated: 1) a greater prevalence in high dose ICS versus other dose groups for 15 ICQ domains; 2) a dose response for the 57 items on the scale; 3) greater convergence between local side effect domains than between systemic and local domains of the scale; and 4) a relationship between ICS dose and ICQ scoring after adjusting for appropriate confounders in multiple regression. Test-retest reliability was measured in 71 randomly selected patients who had no change in their medication use at day 7. The reliability of total and domain scores were calculated between Day 1 and 7 scores, using intraclass correlation coefficients (ICC). RESULTS: All construct validity hypotheses were well supported: there was 1) greater prevalence in the high dose group; 2) a dose response in item scoring; 3) greater convergence between local ICQ domains; and 4) dosage group independently predicted ICQ scoring after adjusting for confounders. The ICQ had good reproducibility: test-retest ICC were ≥0.69 for all but one domain. CONCLUSION: The ICQ shows good construct validity and is a reliable tool for measuring the ICS side effects perceived by adults with asthma. Berlex Laboratories, Wayne, NJ, USA OBJECTIVES: Evaluation of peripheral vascular disease in the primary care setting is routinely performed by contrast enhanced magnetic resonance angiography (ce-MRA) and digital subtraction angiography (DSA). However, limited data is available on the clinical outcomes following these diagnostic procedures. METHODS: We identified individuals who underwent an outpatient ce-MRA (3,444) or DSA (16,899) procedure of the lower extremities from 1998 to 2004 in the U.S. Veterans Health care System. Interventions (revascularization, stent, angioplasty), amputations or mortality rates within one year of DSA or ce-MRA were assessed, while complications within 30 days were compared for both groups adjusted for baseline characteristics using log-binomial regression.RESULTS: Approximately 31% of the patients had an intervention after imaging with a greater proportion having an intervention following DSA (36% vs. 20%; P < 0.001). Similarly, amputations (without interventions) were more common after DSA (8% vs. 4%; P < 0.001). Mortality within one year was comparable in both groups (6.9% vs. 6.2%). Overall complications were 2.0%, majority of the events were vascular complications including hematomas (70.5%). Vascular complications were more frequent following a DSA as compared to ce-MRA (1.7% versus 0.4%). In multivariable-adjusted models complications were lower after a ce-MRA then a DSA procedure (RR, 0.47; 96% CI, 0.34-0.65). CONCLUSIONS: Imaging leading to an intervention occurred only in about a third of subjects. Overall complications rates were low but higher after DSA. A greater understanding of clinical predictors, timing and cost-benefit of diagnostic imaging is needed to determine the best course of action to assess and reduce the morbidity associated with PVD. Recently published data from the second Euro Heart Survey on Acute Coronary Syndromes (ACS) provided a broad view of risk factors (RFs) and care pathways, but some large countries contributed few patients to the registry. This study was performed as a complementary analysis to describe RFs in ACS patients undergoing percutaneous coronary intervention (PCI) in 5 large European countries. METHODS: This was a retrospective study using the IMS Health Acute Cardiovascular Analyzer. This is a physician-reported registry in Germany, France, Italy, Spain, and the UK. Data collection timeframe was January-November 2005. Use of PCI and 7 RFs associated with poor outcomes (age was slightly modified from Wallentin, 2005) were described by country. RESULTS: Over 400 cardiologists reported data on 8979 ACS patients. Patient count by country was: Germany-1624, France-1654, Italy-1608, Spain-2039, UK-2054. Including only patients who underwent PCI and received clopidogrel (n = 4393), the frequency was lowest in the UK (31.0%) and highest in Germany (68.8%). The index diagnosis was: ST-elevation myocardial infarction (MI) 45%, non ST-elevation MI 29%, unstable angina 26%. Distribution of the 7 RFs was: age >65 ranged from 37.8% (UK) to 48.4% (Spain); males 67.9% (Italy) to 75.9% (France). Diabetes ranged from 25% (France) to 35.4% (Germany). Prior MI ranged from 9.6% (France) to 17.6% (Germany). ST-depression occurred in 21.6% (France) to 47.3% (UK), and elevated troponin occurred in 64.4% (UK) to 80.3% (Spain). Elevated serum creatinine occurred in 4.0% (Italy) to 10.2% (Germany). Mean number of risk factors by country was 2.66-Germany, 2.47-France, 2.62-Italy, 2.8-Spain and 2.68-UK. CONCLUSIONS: This large sample of ACS patients provides additional information on important RFs by country and may be useful to construct country-specific outcomes models. PCI was most frequently used in Germany and the number of RFs was highest in Spain.
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CARDIOVASCULAR DISEASE PCV1 CLINICAL IMPACT OF DIAGNOSTIC IMAGING OF LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE

PCV2 CARDIOVASCULAR RISK FACTORS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES
PCV3 DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE?
Pietrasik As reference standard SPECT, scintigraphy or combinations of several tests (e.g. stress electrocardiography, stress echocardiography, angiography) were accepted. We constructed diagnostic 2 × 2-tables from diagnostic test characteristics (e.g., sensitivity, specificity) and performed a diagnostic meta-analysis using the inverse variance approach. RESULTS: Thirteen articles were identified matching the inclusion criteria. Four articles were excluded because of multiple reporting of data. From the 9 studies included, data for 717 observational units (i.e., patient or coronary lesion) were extracted. Pooled sensitivity of FFR was 82% (95%-CI: 77-86%), and specificity was 79% (74-83%). Diagnostic odds ratio was 16.5 (11.4-63.7) . Excluding single studies did not affect these results. Subgroup analyses showed severity of disease reflected by the number of affected coronary vessels as an influential factor on test sensitivity (single-vessel-disease: 95% [87-99%] vs. 78% [73-83%] in multi-vessel-disease). Choice of reference standard also influenced pooled sensitivity. Studies using SPECT as reference standard showed a lower sensitivity than studies using other reference standards (78% [73-83%] vs. 95% [87-99%] ). Subgroups of studies with multivessel-disease patients and studies using SPECT as reference standard tended to be of newer publication date. CONCLUSIONS: FFR is a functional test with sufficiently high sensitivity and specificity for the detection of hemodynamic relevant coronary stenoses. Time trends in the data affecting the overall estimate of pooled sensitivity can not be excluded, but are unlikely to relevantly influence the result.
PCV5 DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES
Eisenstein EL, Tuttle RH, Shaw LK, Anstrom KJ, Kong DF Duke Clinical Research Institute, Durham, NC, USA OBJECTIVE: Drug-eluting stents (DES) have become the principal coronary artery revascularization modality in the US; yet little is known about their long-term clinical outcomes versus bare-metal stents (BMS). We examined 2-year clinical event rates for BMS vs. DES in a practice-based population and compared results for patients with single-as well as multi-vessel coronary artery disease (CAD). METHODS: The study population includes Duke University Medical Center patients undergoing revascularization with BMS or DES between January 1, 2000 and May 31, 2005, with follow-up through August 17, 2006. Study outcomes examined are death, non-fatal myocardial infarction (MI), and target vessel revascularization (TVR), and their composites. RESULTS: We examined the data of 3678 BMS and 1689 DES patients. DES vs. BMS patients had more multivessel CAD (42.6% vs. 36.6%). At two years follow-up, DES vs. BMS patients had lower rates of mortality (7.8% vs. 8.6%), nonfatal MI (3.3% vs. 5.0%), and TVR (6.0% vs. 14.2%). This difference in DES vs. BMS TVR rate was observed in patients with 1-(5.5% vs. 13.0%), 2-(6.7% vs. 15.7%), and 3-vessel CAD (7.0% vs. 18.8%). After adjustment for differences in baseline characteristics using Cox proportional hazards modeling, DES vs. BMS use was associated with no difference in mortality; but with significant reductions in the composites of death or MI (HR = 0.81, 95% CI = 0.67, 0.98) and death, MI, or TVR (HR = 0.55, 95% CI = 0.47, 0.64). Event reduction in the adjusted models was not limited to 1-, 2-, or 3-vessel CAD patients. CON-CLUSIONS: The use of drug-eluting vs. bare-metal stents is associated with significant improvements in long-term clinical outcomes for patients with single-and multi-vessel coronary artery disease.
PCV6 REACHING SIGN CHOLESTEROL TARGETS AND BEYOND: RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN A SCOTTISH GENERAL PRACTICE
Burnett GR
Princes Street Surgery, Thurso, Scotland, UK, 2 AstraZeneca UK, Luton, UK OBJECTIVES: Scottish Intercollegiate Guidelines Network (SIGN) guidelines advise that at risk patients should be treated to a total cholesterol (TC) target of <5 mmol/L. Recent Joint British Societies Guidelines (JBS2, 2005) recommend patients be treated to a lower TC target of <4 mmol/L. An audit was conducted to determine the effect of the new guidelines on the proportion of patients achieving target cholesterol levels with rosuvastatin. METHODS: General Practice records were searched to identify patients who had been prescribed rosuvastatin 10 mg and the following data recorded: previous statin therapy, last cholesterol result on that statin and first cholesterol test on rosuvastatin 10 mg. RESULTS: A total of 508 patients who had previously been prescribed rosuvastatin 10 mg were identified. Of these 376 had both a pre-and post-rosuvastatin treatment total cholesterol test. The majority of patients were statin-naive (n = 253), the others had previously been prescribed atorvastatin, mean dose 14 mg (n = 102), simvastatin mean dose 19 mg (n = 22) or pravastatin mean dose 15 mg (n = 2). Prior to treatment with rosuvastatin 13% (49/376) had a TC <5 mmol/L, increasing to 81% (303/376) after treatment with rosuvastatin 10 mg. In previously statin naïve patients 82% (208/253) achieved TC <5 mmol/L on rosuvastatin compared to 77% (95/123) in patients who had previously been treated with another statin. On average patients experienced a 1.6 mmol/L (27%) reduction in TC (32% in statin naïve, 16% where statin changed). Improvements were also seen against JBS2 targets; patients with TC <4 mmol/L improved from 3% (11/376) prior to rosuvastatin to 35% (131/376) on rosuvastatin 10 mg (37% in statin naïve, 30% where statin changed). CONCLUSIONS:
